Evers J, Hendriks LEL, De Jaeger K, et al. - Analyzing stage I-III small cell lung cancer (SCLC) treatment trends in the Netherlands over the period 2008-2019, variations were evident in the treatment regimens and radiotherapy fractionation schemes between patient groups, regions and hospitals.

• Surgery was increasingly used in stage I, employed in 29% (patients) in 2008-2009 and in 44% in 2018-2019.

• Combined use of chemotherapy and radiotherapy reduced in stage I (from 47% to 15%), was constant (64%) in stage II, and rose in stage III, from 57% (2008) to 70% (2019).

• In stages II and III, an increase in use of concurrent (cCRT) vs sequential chemoradiation (sCRT) was evident over time (odds ratio _{2008-2011 vs 2016-2019} : 0.53), and acceleration was seen in most radiotherapy in cCRT since 2012.